Overview Filtered Trial for Amlodipine Non-responder Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy. Phase: Phase 3 Details Lead Sponsor: Boehringer IngelheimTreatments: AmlodipineTelmisartanTelmisartan amlodipine combination